Place · Level 3
Ashwagandha · Withania somnifera
印度阿育吠陀 3000 年 · 适应原概念代表 · 皮质醇 RCT 证据 B 级 · 提取物形式差异巨大
Story path
Chapter 1
3000 yr Ayurveda
3000 yr Ayurveda
The name Ashwagandha comes from Sanskrit, combining 'horse smell' and 'strength of a horse'.
Foundational facts:
Latin name Withania somnifera, a Solanaceae shrubThe main medicinal part is the root; leaves and berries have different traditional uses and safety profiles3000 years of Ayurvedic use, in India, Nepal, and South AsiaAyurveda classifies it as a rasayana (rejuvenator / adaptogen), traditionally used to improve vitality, sexual function, memory, and longevity
On the concept of adaptogen, introduced by Soviet pharmacologist Lazarev in 1947 and systematized by Brekhman + Dardymov in 1969, with three defining features:
1. Non-toxic at normal doses
2. Non-specific — effective against multiple stressors
3. 'Normalizing' action — returns the body to homeostasis, whether starting from too high or too low
Classic adaptogens typically listed: ashwagandha, rhodiola, ginseng, cordyceps, holy basil, schisandra. The word has no formal FDA/EMA recognition and lives mostly in marketing and integrative medicine, but some of these plants do have RCT evidence — ashwagandha is among them.
Main active compounds
Withanolides: a class of steroidal lactones, ashwagandha's main pharmacologically active substance. Most-studied are withaferin A, withanolide A, withanone. Chemical structure resembles glucocorticoids, so partial effects may go through GR (glucocorticoid receptor) modulation; also acts on GABA / dopamine / serotonin systemsWithanosides: glycosylated withanolidesAlkaloids: trace amounts, used as a sedative in ancient India
Root vs leaf
Traditional use and most RCTs use root, because root has high withanolide content and few alkaloid impurities. Leaf extracts have higher withaferin A but also more cytotoxicity; some commercial products mix leaf and root, possibly explaining some adverse event reports. KSM-66, Sensoril and other proprietary extracts are standardized — see the next scene.
Foundational facts:
Latin name Withania somnifera, a Solanaceae shrubThe main medicinal part is the root; leaves and berries have different traditional uses and safety profiles3000 years of Ayurvedic use, in India, Nepal, and South AsiaAyurveda classifies it as a rasayana (rejuvenator / adaptogen), traditionally used to improve vitality, sexual function, memory, and longevity
On the concept of adaptogen, introduced by Soviet pharmacologist Lazarev in 1947 and systematized by Brekhman + Dardymov in 1969, with three defining features:
1. Non-toxic at normal doses
2. Non-specific — effective against multiple stressors
3. 'Normalizing' action — returns the body to homeostasis, whether starting from too high or too low
Classic adaptogens typically listed: ashwagandha, rhodiola, ginseng, cordyceps, holy basil, schisandra. The word has no formal FDA/EMA recognition and lives mostly in marketing and integrative medicine, but some of these plants do have RCT evidence — ashwagandha is among them.
Main active compounds
Withanolides: a class of steroidal lactones, ashwagandha's main pharmacologically active substance. Most-studied are withaferin A, withanolide A, withanone. Chemical structure resembles glucocorticoids, so partial effects may go through GR (glucocorticoid receptor) modulation; also acts on GABA / dopamine / serotonin systemsWithanosides: glycosylated withanolidesAlkaloids: trace amounts, used as a sedative in ancient India
Root vs leaf
Traditional use and most RCTs use root, because root has high withanolide content and few alkaloid impurities. Leaf extracts have higher withaferin A but also more cytotoxicity; some commercial products mix leaf and root, possibly explaining some adverse event reports. KSM-66, Sensoril and other proprietary extracts are standardized — see the next scene.
Why this one is most-studied
Ashwagandha has the most RCT data of any adaptogen, due to several stacked reasons:1. Indian government research support: the AYUSH ministry (Ayurveda, Yoga, Unani, Siddha, Homeopathy) funds modernization of traditional medicines, and CSIR (Council of Scientific & Industrial Research) runs multiple ashwagandha research centers; many RCTs are run in Indian clinical hospitals (Sri Sri, KARE, etc.).
2. Perfectly fits the chronic-stress Western era theme: modern life is widely high in cortisol / inflammation / poor sleep / anxiety, and market demand for 'natural + cortisol-regulating' products is large — ashwagandha slots straight into that market.
3. Commercial drivers: KSM-66 (Ixoreal Biomed) is an Indian-developed standardized extract that has funded multiple RCTs; Sensoril (Natreon) is another standardized extract. Patented extract + RCTs = academic data + commercial moat.
4. Signals in multiple clinical domains: stress / anxiety (core), sleep, male fertility / T level (limited), muscle strength / exercise performance, cognition / memory, subclinical thyroid — not a single indication, broad marketing room.
5. Rising Western mainstream acceptance: after 2020, Instagram / TikTok #ashwagandha racked up billions of views, pushed by KOLs like Joe Rogan; US sales rose from $35M in 2018 to $300M+ in 2023.
But these reasons make it popular, not necessarily effective for you. Real effectiveness depends on RCT quality, dose, extract form, and your specific indication. The next scenes break each of these down.
Chapter 2
HPA modulation · cortisol hypothesis
HPA modulation · cortisol hypothesis
Ashwagandha's main hypothesized mechanism is lowering cortisol and modulating the hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol. axis, but the actual biochemistry spans several layers.
① Direct HPA modulation
Withanolides may inhibit CRH / ACTH release, reducing the magnitude of acute stress-induced cortisol spikes. Multiple RCTs measuring blood or salivary cortisol show 14–32% reduction after 8–12 weeks of use:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64 chronically stressed adults, KSM-66 600 mg/day × 60 days, serum cortisol ↓27.9% (vs placebo ↓7.9%) — note: the original trial measured morning *serum*, not salivaryLopresti 2019 (*Medicine*): N=60 stressed adults, 240 mg/day × 60 days, morning cortisol ↓
② GABAergic action
Withanolides partially bind GABA-A receptors, producing a mild benzodiazepine-like sedation. This may be the mechanistic basis for anxiety and sleep improvement, parallel to cortisol reduction.
③ Neurotransmitter modulation
Some animal studies show ashwagandha may upregulate serotonin and dopamine; some RCTs report improvements in depression / anxiety scores.
④ Antioxidant and anti-inflammatory
Withanolides show anti-inflammatory activity in vitro and in animals (nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. inhibition, COX-2 inhibition); some RCTs observe mild drops in C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'., interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation., and other inflammation markers.
⑤ Thyroid modulation
Sharma 2018 (*J Altern Complement Med*): N=50 subclinical hypothyroid, 600 mg/day × 8 weeks → T3 + T4 ↑, thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. ↓. This is also why hyperthyroid patients are theoretically contraindicated — it may worsen hyperthyroidism; Hashimoto and subclinical hypothyroid may benefit, but evidence is still preliminary.
Mechanism summary — two boundaries
Evidence-backed: cortisol RCT replicated multiple times (~15–25% drop), subjective stress scores dropHypothesis stage: neurotransmitter, anti-inflammatory, thyroid, sexual function — early evidence, awaiting replicationNo evidence at all: marketing claims like 'anti-aging / skin whitening / direct fat loss'
'Cortisol drop = stress reduction' needs careful interpretation
Lowering cortisol per se doesn't equal health improvement — cortisol is a normal stress response, and too low is also bad (Addison's disease). The key is rhythm restoration (morning high, evening low); ashwagandha probably works more through this path than simple absolute reduction.
Using ashwagandha to replace addressing the root causes of stress (work, sleep, relationships, finances) treats a chemical agent as a cure-all — a common marketing trap.
① Direct HPA modulation
Withanolides may inhibit CRH / ACTH release, reducing the magnitude of acute stress-induced cortisol spikes. Multiple RCTs measuring blood or salivary cortisol show 14–32% reduction after 8–12 weeks of use:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64 chronically stressed adults, KSM-66 600 mg/day × 60 days, serum cortisol ↓27.9% (vs placebo ↓7.9%) — note: the original trial measured morning *serum*, not salivaryLopresti 2019 (*Medicine*): N=60 stressed adults, 240 mg/day × 60 days, morning cortisol ↓
② GABAergic action
Withanolides partially bind GABA-A receptors, producing a mild benzodiazepine-like sedation. This may be the mechanistic basis for anxiety and sleep improvement, parallel to cortisol reduction.
③ Neurotransmitter modulation
Some animal studies show ashwagandha may upregulate serotonin and dopamine; some RCTs report improvements in depression / anxiety scores.
④ Antioxidant and anti-inflammatory
Withanolides show anti-inflammatory activity in vitro and in animals (nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. inhibition, COX-2 inhibition); some RCTs observe mild drops in C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'., interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation., and other inflammation markers.
⑤ Thyroid modulation
Sharma 2018 (*J Altern Complement Med*): N=50 subclinical hypothyroid, 600 mg/day × 8 weeks → T3 + T4 ↑, thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. ↓. This is also why hyperthyroid patients are theoretically contraindicated — it may worsen hyperthyroidism; Hashimoto and subclinical hypothyroid may benefit, but evidence is still preliminary.
Mechanism summary — two boundaries
Evidence-backed: cortisol RCT replicated multiple times (~15–25% drop), subjective stress scores dropHypothesis stage: neurotransmitter, anti-inflammatory, thyroid, sexual function — early evidence, awaiting replicationNo evidence at all: marketing claims like 'anti-aging / skin whitening / direct fat loss'
'Cortisol drop = stress reduction' needs careful interpretation
Lowering cortisol per se doesn't equal health improvement — cortisol is a normal stress response, and too low is also bad (Addison's disease). The key is rhythm restoration (morning high, evening low); ashwagandha probably works more through this path than simple absolute reduction.
Using ashwagandha to replace addressing the root causes of stress (work, sleep, relationships, finances) treats a chemical agent as a cure-all — a common marketing trap.
Cortisol + stress more nuanced
The cortisol-stress relationship is more nuanced than popular understanding. A few easily-missed points:1. 'High cortisol = stress' is an oversimplification
In healthy people, short-term cortisol rises during stress are adaptive and a good thing. Chronic stress disrupts cortisol rhythm (flattened or inverted), not necessarily raising the average. A meaningful fraction of patients with depression, stress-related fatigue, and chronic fatigue syndrome actually have LOW cortisol and blunted responses.
2. The logic of cortisol-lowering treatment
Truly stressed people: cortisol lowering may restorePeople with already-normal cortisol: lowering it may be pointless or harmful
This explains why ashwagandha shows large individual variation — clear effect in 'stressed groups', vague effect in healthy controls.
3. RCT design limits
Most ashwagandha RCTs enroll people with high stress scores, not ordinary healthy people. Extrapolating to healthy populations needs caution — energetic people without obvious anxiety are unlikely to benefit, and may blunt their stress response.
4. The science of stress management
The core of recovery science is 'rhythm + appropriate stimulus', not 'always low stress'. HRV (heart rate variability) is a better stress indicator than absolute cortisol. Real stress interventions include:
Sleep 7–9 h: the strongest intervention, far exceeding any supplementRegular exercise: acute cortisol ↑, long-term ↓Mindfulness / meditation: RCT-supported for cortisol reductionSocial connection and nature exposureLimit caffeine and screen blue light
5. Ashwagandha's reasonable role
An adjunct, added on top of basic interventions — not a replacement4–8 week trial, watching HRV / sleep / subjective stress score for changeNo response → stop, don't faith-based long-term useSevere anxiety / depression / PTSD: see a professional, not an ashwagandha trial
Chemical adjuncts are vastly inferior to lifestyle redesign — a common conclusion across nearly all nutritional medicine topics, especially in the adaptogen category.
Chapter 3
RCT evidence · stress / sleep / muscle
RCT evidence · stress / sleep / muscle
Ashwagandha's clinical RCT evidence stratified by strength.
B-tier (moderate evidence, multiple RCTs but small samples, data mostly from India)
① Chronic stress + anxiety:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64, KSM-66 300 mg × 2/day × 60 days, PSS stress score ↓44%, serum cortisol ↓27.9% (vs placebo ↓7.9%)Lopresti 2019 (*Medicine*, Australia): N=60, 240 mg/day × 60 days, HADS anxiety score ↓Salve 2019 (*Cureus*, India): N=60, KSM-66 250–600 mg/day × 8 wk, anxiety + sleep improvedPratte 2014 review: 5 RCTs show consistent improvement, but samples small, data mostly from India, many KSM-66 company-funded
② Sleep:
Langade 2019 (*Cureus*): N=80 insomniacs, 300 mg × 2/day × 8 wk, sleep efficiency ↑7.9%, latency ↓Salve 2019 also observed improvementMechanism likely GABA + sedation + cortisol rhythm
③ Male T + fertility:
Lopresti 2019 (*Am J Men's Health*): N=43, 240 mg × 16 wk, serum T ↑14.7%, DHEA-S ↑Ambiye 2013 (*Evid Based Complement Altern Med*): N=46 infertile men, KSM-66 675 mg × 90 days, sperm concentration ↑167%, semen volume ↑53%, motility ↑57% — striking numbers but need large-sample replicationClinical meaning: signal for fertility adjunct, not a replacement for proper reproductive medicine
④ Muscle strength + exercise:
Wankhede 2015 (*J Int Soc Sports Nutr*): N=57 male strength trainees, KSM-66 600 mg × 8 wk, bench press (Δ +46 vs +26 kg) + leg extension (Δ +14.5 vs +9.8 kg) + muscle cross-sectional area ↑Ziegenfuss 2018 (*Nutrients*): N=18 elite athletes, similar resultsEffect size larger than typical supplements; mechanism may be T ↑, cortisol ↓, improved recovery
C-tier (early or single studies)
Subclinical thyroid: Sharma 2018, single studyCognition / memory: a few small studies (Choudhary 2017 etc.)Depression: as antidepressant adjunct (Chengappa 2013 bipolar), earlyOCD: Jahanbakhsh 2016, small study
Claims without evidence (these don't survive scrutiny): longevity / anti-aging, skin whitening, direct fat loss, immune activation.
Several RCT data limitations
Most samples <100, conducted in IndiaMany studies funded by KSM-66 company (Ixoreal Biomed) — doesn't negate results but raises publication bias riskLack of long-term data beyond 6 monthsWestern-population RCTs still scarceNo specific indication approved by FDA or EMA — it's a dietary supplement, not a drug
B-tier (moderate evidence, multiple RCTs but small samples, data mostly from India)
① Chronic stress + anxiety:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64, KSM-66 300 mg × 2/day × 60 days, PSS stress score ↓44%, serum cortisol ↓27.9% (vs placebo ↓7.9%)Lopresti 2019 (*Medicine*, Australia): N=60, 240 mg/day × 60 days, HADS anxiety score ↓Salve 2019 (*Cureus*, India): N=60, KSM-66 250–600 mg/day × 8 wk, anxiety + sleep improvedPratte 2014 review: 5 RCTs show consistent improvement, but samples small, data mostly from India, many KSM-66 company-funded
② Sleep:
Langade 2019 (*Cureus*): N=80 insomniacs, 300 mg × 2/day × 8 wk, sleep efficiency ↑7.9%, latency ↓Salve 2019 also observed improvementMechanism likely GABA + sedation + cortisol rhythm
③ Male T + fertility:
Lopresti 2019 (*Am J Men's Health*): N=43, 240 mg × 16 wk, serum T ↑14.7%, DHEA-S ↑Ambiye 2013 (*Evid Based Complement Altern Med*): N=46 infertile men, KSM-66 675 mg × 90 days, sperm concentration ↑167%, semen volume ↑53%, motility ↑57% — striking numbers but need large-sample replicationClinical meaning: signal for fertility adjunct, not a replacement for proper reproductive medicine
④ Muscle strength + exercise:
Wankhede 2015 (*J Int Soc Sports Nutr*): N=57 male strength trainees, KSM-66 600 mg × 8 wk, bench press (Δ +46 vs +26 kg) + leg extension (Δ +14.5 vs +9.8 kg) + muscle cross-sectional area ↑Ziegenfuss 2018 (*Nutrients*): N=18 elite athletes, similar resultsEffect size larger than typical supplements; mechanism may be T ↑, cortisol ↓, improved recovery
C-tier (early or single studies)
Subclinical thyroid: Sharma 2018, single studyCognition / memory: a few small studies (Choudhary 2017 etc.)Depression: as antidepressant adjunct (Chengappa 2013 bipolar), earlyOCD: Jahanbakhsh 2016, small study
Claims without evidence (these don't survive scrutiny): longevity / anti-aging, skin whitening, direct fat loss, immune activation.
Several RCT data limitations
Most samples <100, conducted in IndiaMany studies funded by KSM-66 company (Ixoreal Biomed) — doesn't negate results but raises publication bias riskLack of long-term data beyond 6 monthsWestern-population RCTs still scarceNo specific indication approved by FDA or EMA — it's a dietary supplement, not a drug
Extract forms differ greatly
Ashwagandha isn't one thing — the commercial market splits into at least 4 categories.① Whole root powder — traditional form
Traditional dose 5–10 g/day, taken with warm milk + honey, withanolide content 0.2–0.5%. Pros: complete food matrix, low cost. Cons: hard to standardize, rarely used in modern RCTs.
② KSM-66 (Ixoreal Biomed) — the most widely RCT-studied standardized extract
Withanolide content ≥5% (standardized)Root-only extraction, no leaf, water-based not ethanolMost modern RCTs use thisTypical dose 300 mg × 2/day or 600 mg/dayMany brands use KSM-66 raw material (Nutritional Frontiers / NOW / Sports Research, etc.)
③ Sensoril (Natreon) — another standardized extract
Withanolide ≥10% (higher concentration)Contains leaf + root, safety debatedTypical dose 125–250 mg/day (relatively low)Some RCTs use it
④ Self-standardized / generic extracts — most cheap brands
Labels say 'contains X% withanolides' but actual content varies (ConsumerLab has repeatedly found discrepancies). Products without third-party certification are risky and may contain impurities or heavy metals.
KSM-66 vs Sensoril selection:
Stress + anxiety: most RCTs use KSM-66 600 mg/daySleep: KSM-66 300 mg or Sensoril 250 mg both have dataMale T + muscle: KSM-66 600 mg/daySubclinical thyroid: early data uses KSM-66
Dose ceiling and safety
Highest RCT dose 1000 mg/day; 300–600 mg is usually enough. In the adaptogen concept, small dose long-term is usually better than large dose short-term; don't exceed 12 weeks of uninterrupted use, because long-term data is lacking — a 'drug holiday' is the conservative approach.
4-week trial decision flow:
1. Baseline measurement: stress score (PSS-10), sleep diary, subjective vitality
2. Take KSM-66 600 mg/day × 4 weeks
3. Retest: ≥20% improvement → continue 4 weeks; no change → stop
4. Don't exceed 12 weeks continuous use
5. Watch for side effects: GI upset, drowsiness, any bodily changes
Chapter 4
Side effects + contraindications
Side effects + contraindications
Ashwagandha is NOT a 'natural food with no side effects' — FDA-unregulated doesn't equal risk-free.
Common (≥1%) side effects: GI upset (nausea, diarrhea) ~5–10% (RCT data); drowsiness (consistent with GABA action, usually solvable by dose adjustment); mild headache; fishy or aftertaste.
Rare but important
① Hepatotoxicity (DILI, drug-induced liver injury):
Iceland 2018 + Australia + US 2019–2023 multiple case reports: ashwagandha users developing acute liver injury, with transaminase spikes and bilirubin ↑Most reversible after stopping, but liver transplant cases have been reported**Björnsson 2020 *Liver International***: 5 cases attributed to ashwagandhaMechanism unclear, possibly individual susceptibility, impurities, or stacked drug interactionsRisk factors: pre-existing liver disease, polypharmacy, high doseRecommendation: avoid in those with liver disease history; monitoring ALT / AST during use is reasonable
② Thyroid function effects:
Ashwagandha may raise T3 + T4 (basis for subclinical hypothyroidism studies)Hyperthyroid patients: theoretically contraindicated, may worsenHashimoto / on levothyroxine: monitor dose, may need to reduce medicationHealthy thyroid: usually no effect, but sensitive individuals are exceptions
③ Pregnancy + lactation:
Traditional Ayurveda also used it during pregnancy, but the preparations differModern concerns: withanolides' steroidal structure could theoretically affect hormones and the uterusAnimal studies: high doses induce abortionRecommendation: avoid in pregnancy — not worth taking unknown risks for stress relief
④ Autoimmune disease:
Ashwagandha may modulate immunity, theoretically worsening some autoimmune diseases (lupus, MS, RA, Hashimoto). Data are mixed; real risk is unknown. Patients with diagnosed autoimmune disease should discuss with a doctor before deciding.
⑤ Drug interactions:
Sedatives (BZD, sleep aids, opioids): synergistic sedation, potentially dangerousAntidiabetics: ashwagandha may lower blood sugar; combined with medications may cause hypoglycemiaAntihypertensives: similarThyroid medications: see aboveImmunosuppressants: theoretical antagonismStop 2 weeks pre-surgery (anesthesia synergy + bleeding)
Absolute contraindications:
Pregnancy, trying to conceive (female)Hyperthyroidism (Graves' disease, etc.)Taking thyroid medications without monitoringPrior liver disease or currently on hepatotoxic drugs2 weeks pre-surgeryChildren (<18, no safety data)
Relative contraindications (use with caution after discussion): autoimmune disease (lupus, MS, type 1 diabetes, RA, Hashimoto); polypharmacy; diagnosed depression or anxiety + on medication (discuss with psychiatrist).
'Natural = safe' is a big mistake here — ashwagandha is a compound with genuine pharmacological activity. Use should involve a doctor or pharmacist before and during, not be driven by random purchases on Instagram.
Common (≥1%) side effects: GI upset (nausea, diarrhea) ~5–10% (RCT data); drowsiness (consistent with GABA action, usually solvable by dose adjustment); mild headache; fishy or aftertaste.
Rare but important
① Hepatotoxicity (DILI, drug-induced liver injury):
Iceland 2018 + Australia + US 2019–2023 multiple case reports: ashwagandha users developing acute liver injury, with transaminase spikes and bilirubin ↑Most reversible after stopping, but liver transplant cases have been reported**Björnsson 2020 *Liver International***: 5 cases attributed to ashwagandhaMechanism unclear, possibly individual susceptibility, impurities, or stacked drug interactionsRisk factors: pre-existing liver disease, polypharmacy, high doseRecommendation: avoid in those with liver disease history; monitoring ALT / AST during use is reasonable
② Thyroid function effects:
Ashwagandha may raise T3 + T4 (basis for subclinical hypothyroidism studies)Hyperthyroid patients: theoretically contraindicated, may worsenHashimoto / on levothyroxine: monitor dose, may need to reduce medicationHealthy thyroid: usually no effect, but sensitive individuals are exceptions
③ Pregnancy + lactation:
Traditional Ayurveda also used it during pregnancy, but the preparations differModern concerns: withanolides' steroidal structure could theoretically affect hormones and the uterusAnimal studies: high doses induce abortionRecommendation: avoid in pregnancy — not worth taking unknown risks for stress relief
④ Autoimmune disease:
Ashwagandha may modulate immunity, theoretically worsening some autoimmune diseases (lupus, MS, RA, Hashimoto). Data are mixed; real risk is unknown. Patients with diagnosed autoimmune disease should discuss with a doctor before deciding.
⑤ Drug interactions:
Sedatives (BZD, sleep aids, opioids): synergistic sedation, potentially dangerousAntidiabetics: ashwagandha may lower blood sugar; combined with medications may cause hypoglycemiaAntihypertensives: similarThyroid medications: see aboveImmunosuppressants: theoretical antagonismStop 2 weeks pre-surgery (anesthesia synergy + bleeding)
Absolute contraindications:
Pregnancy, trying to conceive (female)Hyperthyroidism (Graves' disease, etc.)Taking thyroid medications without monitoringPrior liver disease or currently on hepatotoxic drugs2 weeks pre-surgeryChildren (<18, no safety data)
Relative contraindications (use with caution after discussion): autoimmune disease (lupus, MS, type 1 diabetes, RA, Hashimoto); polypharmacy; diagnosed depression or anxiety + on medication (discuss with psychiatrist).
'Natural = safe' is a big mistake here — ashwagandha is a compound with genuine pharmacological activity. Use should involve a doctor or pharmacist before and during, not be driven by random purchases on Instagram.
DILI case timeline
The ashwagandha hepatotoxicity reporting timeline is enough to shatter the 'natural = safe' illusion.2018 Iceland (Björnsson et al.): 5 cases of acute liver injury attributed to ashwagandha, all after 8–12 weeks of use, with transaminase spikes; most recovered in 1–3 months after stopping, 1 required steroid treatment.
2019–2020 multi-country follow-up reports:
US DILIN network: 4 casesAustralia TGA: 3 cases + 1 death (combined with multiple herbal supplements, hard to attribute solely to ashwagandha)Japan: 2 cholestatic liver injury cases
**2023 review (Philips 2023 *Hepatology Communications*)**:
Globally, ~30 cumulative ashwagandha-related DILI casesMostly cholestatic type (jaundice + ALP / GGT ↑)Most recovered after stopping, rarely needing liver transplantMechanism hypotheses: individual CYP / UGT polymorphisms; impurities or heavy metal contamination in some sources; leaf-containing extracts (high withaferin A) possibly more toxic than pure rootThis is an idiosyncratic reaction with no clear dose-response threshold, hard to predict
Comparison with other 'natural' DILI: green tea extract (high EGCG) is a major hepatotoxic herb; He Shou Wu (TCM herb) has multiple reports; black cohosh (menopause) supplement has many cases; green coffee bean; Hydroxycut (weight loss); large mixed-protein supplement blends.
US DILIN (Drug-Induced Liver Injury Network) data show herbs + dietary supplements account for ~20% of acute DILI and rising, mainly because of loose regulation, low user self-reporting (not telling doctors), and underestimation of real associations.
Practical recommendations:
1. During ashwagandha use, monitor subjective symptoms: jaundice, upper abdominal pain, tea-colored urine, extreme fatigue
2. Ideal practice: test ALT / AST / ALP / bilirubin before starting, at 4 weeks, and at 12 weeks — especially with multiple supplements
3. Any concern, stop immediately and see a doctor
4. Tell every physician and dentist you take ashwagandha, to avoid drug interactions and anesthesia risk
Conclusion: ashwagandha is NOT 'safe and harmless' — it's 'relatively safe for most people under reasonable use'; but rare-yet-real hepatotoxicity makes it UNSUITABLE for 'insurance-style daily use', and only justified under a specific indication + monitoring + time-limited framework.
Chapter 5
vs other adaptogens
vs other adaptogens
Putting ashwagandha alongside other common adaptogens for comparison.
Rhodiola rosea (Siberian alpine plant)
Actives: salidroside + rosavinTraditional use: Russia and Nordic alpine regions, anti-fatigue + altitude toleranceCharacter: activating type (energizing / anti-fatigue / cognition improvement) — opposite of ashwagandha's sedating typeRCT evidence: short-term anti-fatigue and cognition (Olsson 2009 etc.), B-tier moderate evidenceDose: 200–600 mg standardized extract (3% rosavin / 1% salidroside)Timing: take in the morning to start the day; don't take in the evening — can cause insomnia
Panax ginseng (Asian) + Panax quinquefolius (American)
Actives: ginsenosides (Rb1, Rg1, etc., over 30 forms)Traditional use: East Asia and North America for over 2000 yearsCharacter: mild activating, similar to rhodiolaRCT evidence: cognition (Park 2014), American ginseng for postprandial glucose in diabetes (Vuksan 2000+), anti-fatigue in cancer / chemo-related fatigue (Barton 2013), limited erectile function evidence for red ginseng in menVariety differences (TCM): Korean red (warming) / Chinese white (neutral) / American (cooling)Dose: 200–400 mg standardized extract
Holy basil / Tulsi (Ocimum sanctum): a classic Indian Ayurvedic adaptogen, sedative + stress-modulating like ashwagandha, but with less data, mostly used as tea or extract.
Cordyceps: fungus; traditional *C. sinensis* forms from a moth larva infection; modern products use cultured *C. militaris*. Marketing focuses on energy / adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. / exercise performance; RCT evidence is weak-to-moderate, possibly small improvements in high-intensity exercise performance.
Schisandra (five-flavor berry, East Asian): five flavors (sour, sweet, bitter, pungent, salty); anti-fatigue and liver protection data exists in animals, few human RCTs.
Eleuthero (Siberian 'ginseng', not real ginseng): Latin *Eleutherococcus senticosus*, used historically by Soviet athletes and cosmonauts, anti-fatigue data exists but is variable quality.
Adaptogen selection decisions:
Stress / anxiety / sleep → ashwagandha (KSM-66)Fatigue / poor focus / morning low energy → rhodiola or ginsengExercise recovery → ashwagandha (muscle strength), some add rhodiola for enduranceHigh-altitude travel → rhodiolaChemo / chronic fatigue → ginseng family, discuss with MDDiabetes adjunct → American ginseng (moderate evidence)
But all of these are adjuncts, not core: the real core is sleep, exercise, diet, stress management, and social connection; adaptogens and other supplements are just adjuncts.
If you want to stack multiple adaptogens, be careful: they hit the same pathways (hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol., neurotransmitters, antioxidants) and stacking may amplify side effects. Trying one at a time over 4–8 weeks is more scientific than dropping a whole stack at once.
Rhodiola rosea (Siberian alpine plant)
Actives: salidroside + rosavinTraditional use: Russia and Nordic alpine regions, anti-fatigue + altitude toleranceCharacter: activating type (energizing / anti-fatigue / cognition improvement) — opposite of ashwagandha's sedating typeRCT evidence: short-term anti-fatigue and cognition (Olsson 2009 etc.), B-tier moderate evidenceDose: 200–600 mg standardized extract (3% rosavin / 1% salidroside)Timing: take in the morning to start the day; don't take in the evening — can cause insomnia
Panax ginseng (Asian) + Panax quinquefolius (American)
Actives: ginsenosides (Rb1, Rg1, etc., over 30 forms)Traditional use: East Asia and North America for over 2000 yearsCharacter: mild activating, similar to rhodiolaRCT evidence: cognition (Park 2014), American ginseng for postprandial glucose in diabetes (Vuksan 2000+), anti-fatigue in cancer / chemo-related fatigue (Barton 2013), limited erectile function evidence for red ginseng in menVariety differences (TCM): Korean red (warming) / Chinese white (neutral) / American (cooling)Dose: 200–400 mg standardized extract
Holy basil / Tulsi (Ocimum sanctum): a classic Indian Ayurvedic adaptogen, sedative + stress-modulating like ashwagandha, but with less data, mostly used as tea or extract.
Cordyceps: fungus; traditional *C. sinensis* forms from a moth larva infection; modern products use cultured *C. militaris*. Marketing focuses on energy / adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. / exercise performance; RCT evidence is weak-to-moderate, possibly small improvements in high-intensity exercise performance.
Schisandra (five-flavor berry, East Asian): five flavors (sour, sweet, bitter, pungent, salty); anti-fatigue and liver protection data exists in animals, few human RCTs.
Eleuthero (Siberian 'ginseng', not real ginseng): Latin *Eleutherococcus senticosus*, used historically by Soviet athletes and cosmonauts, anti-fatigue data exists but is variable quality.
Adaptogen selection decisions:
Stress / anxiety / sleep → ashwagandha (KSM-66)Fatigue / poor focus / morning low energy → rhodiola or ginsengExercise recovery → ashwagandha (muscle strength), some add rhodiola for enduranceHigh-altitude travel → rhodiolaChemo / chronic fatigue → ginseng family, discuss with MDDiabetes adjunct → American ginseng (moderate evidence)
But all of these are adjuncts, not core: the real core is sleep, exercise, diet, stress management, and social connection; adaptogens and other supplements are just adjuncts.
If you want to stack multiple adaptogens, be careful: they hit the same pathways (hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol., neurotransmitters, antioxidants) and stacking may amplify side effects. Trying one at a time over 4–8 weeks is more scientific than dropping a whole stack at once.
Boundaries of 'adaptogen' concept
Is 'adaptogen' actually a useful clinical concept? The academic community is still debating.Supporters:
Mechanistically, the hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol. axis really can be modulated by various plants — not pure fantasyClinical data: some plants (ashwagandha, rhodiola, ginseng) do show RCT evidence on stress / fatigue endpointsEU EMA grants 'Traditional Herbal Registration' (THR) status to certain plants — doesn't require modern RCTs, just decades of documented traditional use
Critics:
The concept is too broad — 'modulates the body back to homeostasis' fits almost any effective drug, lacking specificityHard to measure — stress resistance lacks objective biomarkers (beyond cortisol and HRV)Publication bias — adaptogen RCTs tend to be small and selectively publish positive resultsAlternative medicine packaging — the word 'adaptogen' is used for many plants with no RCT data at all, blurring real vs fake
FDA / EMA stance: 'adaptogen' is not an FDA-recognized disease or sign; sold as a dietary supplement under the DSHEA 1994 framework. The structure-function claim loophole allows 'supports stress response' but not 'treats anxiety'. EMA THR registers some plants but only acknowledges traditional use — not modern medical validation.
Neutral practical stance:
Acknowledge that some plants (ashwagandha, rhodiola, ginseng) have B-tier RCT data and are worth considering as adjunctsDon't accept 'adaptogens can cure or prevent specific diseases' — that's marketing overreachReal stress management = sleep + exercise + diet + psychology + social connection + therapy or medication if needed — the combined effect of these vastly exceeds all adaptogens combined
3 principles of use:
1. Specific goal: not 'I hope to be healthier' but 'my stress score is high, I want to try 4–8 weeks and see if anything changes'
2. Baseline measurement + tracking: without testing you won't know, and testing nothing after a trial is the same
3. Time-limited use: 4–12 week cycles with breaks — no dependence, no long-term faith
Final metaphor: adaptogens are keys that sometimes open a door — but you DON'T NEED this key to enter the room of 'real health change', because that door is ALWAYS OPEN, inside 'adequate sleep + regular exercise + diverse diet + social connection'. Keys are adjuncts — don't let marketing make you think the door is locked without one.